MatchMedi
English

선택지 정리됨

Cervical cancer: 국가별 선택지

이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.

선택지 정리됨고형암최종 확인 2026.06

현재 제공

국가별 선택지를 정리합니다

국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.

아직 하지 않음

치료 선택을 지시하지 않습니다

이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.

출처

공신력 있는 출처 기반

모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.

진료 전 정리할 정보

  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
  • 이 항목은 원문 출처와 함께 의료진에게 확인하세요.

임상시험 검색어

Cervical cancer clinical trial

국가별 선택지

국가별 치료 선택지

공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.

United States

  • Pembrolizumab (Keytruda)[1]FDA-approvedPD-L1 positive, CPS >=1; Recurrent or metastatic cervical cancer after chemotherapy progression. · This is the FDA's 2018 monotherapy indication; it should not be conflated with later first-line chemo-combination use. The approval notice states the indication was under accelerated approval at that time. Current payer access and later-label evolution were not re-verified in this cycle. Confidence/conflicts: High for the U.S. post-chemotherapy PD-L1-positive cervical monotherapy indication; this cycle did not fetch the later U.S. first-line chemo-combination page.
  • Pembrolizumab (Keytruda)[1]FDA-approvedPD-L1 positive, CPS >=1; Recurrent or metastatic cervical cancer after chemotherapy progression. · This is the FDA's 2018 monotherapy indication; it should not be conflated with later first-line chemo-combination use. The approval notice states the indication was under accelerated approval at that time. Current payer access and later-label evolution were not re-verified in this cycle. Confidence/conflicts: High for the U.S. post-chemotherapy PD-L1-positive cervical monotherapy indication; this cycle did not fetch the later U.S. first-line chemo-combination page.
  • conization, total hysterectomy, modified radical hysterectomy with lymphadenectomy, radical trachelectomy, and pelvic exenteration in selected recurrent contexts[2]Standard option (per NCI PDQ)in situ and stage IA/IB/IIA stage-specific management; pelvic exenteration for selected stage IVB/recurrent contexts. · NCI PDQ is an evidence summary, not a personalized surgical recommendation. Fertility goals, stage, tumor size, nodal findings, prior radiation, surgical risk, and local expertise determine whether surgery is discussed. Confidence/conflicts: high for NCI stage-based treatment-option listing; no conflict identified.
  • external-beam radiation therapy (EBRT), brachytherapy, and cisplatin-based concurrent chemoradiation[2]NCI PDQ: standard optionstages IB/IIA, stages IIB/III/IVA, and postoperative high-risk settings where radiation therapy is required. · NCI notes trial variation and that one trial did not show benefit; radiation plan depends on stage, anatomy, nodal disease, prior surgery, and brachytherapy feasibility. Confidence/conflicts: high for NCI evidence summary; no conflict identified beyond NCI's noted trial heterogeneity. Standard of care for locally advanced cervical cancer requiring radiation (NCI PDQ 2025; NCCN; ESGO) — concurrent cisplatin chemoradiation gives a 30-50% reduction in risk of death. Weekly cisplatin 40 mg/m2 is preferred; carboplatin is an alternative when cisplatin is unsuitable. Newer agents (e.g. pembrolizumab per KEYNOTE-A18) are ADDED to this backbone, not substitutes. The 'one trial did not show benefit' note refers to inter-trial heterogeneity among the supporting trials, not to the regimen failing.
  • palliative chemotherapy and systemic therapy options including cisplatin, carboplatin, paclitaxel, topotecan, doxorubicin-class alternatives as applicable, and bevacizumab-containing regimens when appropriate[2]Standard option (per NCI PDQ)PD-L1 status relevant for pembrolizumab options; other chemotherapy options are not biomarker-selected in the NCI summary; stage IVB and recurrent cervical cancer. · This is a broad systemic-therapy category rather than a single regimen. Prior platinum exposure, performance status, symptoms, PD-L1 status, bleeding/fistula risk, renal function, and care goals influence the actual regimen. Confidence/conflicts: medium-high; NCI supports broad treatment categories, but regimen-specific details require label/guideline refresh. No conflict identified.
  • pembrolizumab (Keytruda) with chemoradiotherapy; pembrolizumab with chemotherapy, with or without bevacizumab (Avastin)[3]FDA-approvedPD-L1 CPS >=1 required for persistent/recurrent/metastatic pembrolizumab plus chemotherapy indication; no biomarker stated in FDA's FIGO stage III-IVA chemoradiotherapy approval notice; FIGO 2014 stage III-IVA with chemoradiotherapy; persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 CPS >=1 for pembrolizumab plus chemotherapy with or without bevacizumab. · FDA notices do not define individual eligibility beyond the approved indications. PD-L1 testing is required for the persistent/recurrent/metastatic approval cited here. Confidence/conflicts: high for FDA approval notices; no conflict identified.
  • tisotumab vedotin-tftv (Tivdak)[4]FDA accelerated approvalrecurrent or metastatic cervical cancer with disease progression on or after chemotherapy. · FDA approval notice does not imply individual eligibility, sequencing, safety suitability, or availability at a specific cancer center. Full prescribing information and eye-toxicity precautions require label review. Confidence/conflicts: high for FDA traditional approval notice; no conflict identified.

European Union

  • Pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab[5]EMA authorisedPD-L1 positive, CPS >=1; Persistent, recurrent, or metastatic cervical cancer in adults with PD-L1 CPS >=1. · This verifies central EU authorisation status only. Member-state reimbursement, sequencing against other options, and country-specific commissioning were not verified in this cycle. Confidence/conflicts: High for EU central authorisation language; no reimbursement verification attempted.
  • Pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab[5]EMA authorisedPD-L1 positive, CPS >=1; Persistent, recurrent, or metastatic cervical cancer in adults with PD-L1 CPS >=1. · This verifies central EU authorisation status only. Member-state reimbursement, sequencing against other options, and country-specific commissioning were not verified in this cycle. Confidence/conflicts: High for EU central authorisation language; no reimbursement verification attempted.
  • Pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab[5]EMA authorisedPD-L1 positive, CPS >=1; Persistent, recurrent, or metastatic cervical cancer in adults with PD-L1 CPS >=1. · This verifies central EU authorisation status only. Member-state reimbursement, sequencing against other options, and country-specific commissioning were not verified in this cycle. Confidence/conflicts: High for EU central authorisation language; no reimbursement verification attempted.
  • bevacizumab (Avastin) with paclitaxel plus cisplatin or paclitaxel plus topotecan[6]EMA authorisedadvanced persistent, recurrent, or metastatic cervical cancer. · Bevacizumab risks, including thromboembolic and bleeding/fistula concerns, require label review and clinical judgment. Member-state reimbursement varies. Confidence/conflicts: medium-high; EMA cervical cancer context is clear, but exact indication wording should be refreshed in current SmPC before patient-facing reuse. No conflict identified.
  • pembrolizumab (Keytruda) with chemoradiotherapy, including external beam radiation therapy followed by brachytherapy[5]EMA authorisedno PD-L1 requirement stated for this EMA indication; adults with FIGO 2014 stage III-IVA locally advanced cervical cancer; no prior definitive therapy. · EMA central authorization does not determine individual member-state reimbursement, hospital protocol, or eligibility. Germany/France HTA and national reimbursement remain separate cells. Confidence/conflicts: high for EMA indication; no conflict identified.
  • pembrolizumab (Keytruda) with chemotherapy, with or without bevacizumab (Avastin and biosimilars)[5]EMA authorisedPD-L1 CPS >=1; persistent, recurrent, or metastatic cervical cancer in adults with PD-L1 CPS >=1. · EMA approval is not the same as automatic access in every EU member state. PD-L1 testing and national reimbursement should be checked. Confidence/conflicts: high for EMA indication; no conflict identified.
  • tisotumab vedotin (Tivdak)[7]EMA authorisedrecurrent or metastatic cervical cancer after previous systemic treatment. · EMA central authorization does not equal reimbursement or availability in every EU member state. Full SmPC safety instructions should be reviewed, especially eye-related precautions. Confidence/conflicts: high for EMA indication; no conflict identified.

United Kingdom

  • Pembrolizumab plus chemotherapy with or without bevacizumab[8]NICE recommendedPD-L1 positive, CPS >=1; Persistent, recurrent, or metastatic cervical cancer in adults with PD-L1 CPS >=1. · This is a NICE access recommendation rather than a pan-UK regulator label. It includes a 2-year stopping rule and commercial-arrangement condition, and should not be generalized to all devolved UK decisions without local verification. Confidence/conflicts: High for NICE recommendation scope and caveats.
  • Pembrolizumab plus chemotherapy with or without bevacizumab[8]NICE recommendedPD-L1 positive, CPS >=1; Persistent, recurrent, or metastatic cervical cancer in adults with PD-L1 CPS >=1. · This is a NICE access recommendation rather than a pan-UK regulator label. It includes a 2-year stopping rule and commercial-arrangement condition, and should not be generalized to all devolved UK decisions without local verification. Confidence/conflicts: High for NICE recommendation scope and caveats.
  • Pembrolizumab plus chemotherapy with or without bevacizumab[8]NICE recommendedPD-L1 positive, CPS >=1; Persistent, recurrent, or metastatic cervical cancer in adults with PD-L1 CPS >=1. · This is a NICE access recommendation rather than a pan-UK regulator label. It includes a 2-year stopping rule and commercial-arrangement condition, and should not be generalized to all devolved UK decisions without local verification. Confidence/conflicts: High for NICE recommendation scope and caveats.
  • cervical surgery options including removal of part of the cervix, fertility-sparing cervix/upper-vagina surgery, hysterectomy-based surgery, lymph-node removal, and pelvic exenteration in selected recurrence contexts[9]Established standard of careearly cervical cancer; selected recurrent disease where other treatment is not possible. · NHS guidance is broad public guidance and not a full specialist guideline. Stage, tumor size, fertility goals, prior treatment, nodal status, and surgical fitness determine whether any surgery is discussed. Confidence/conflicts: medium-high; NHS source supports broad treatment categories, but specialist guideline detail remains a gap. No conflict identified.
  • chemoradiotherapy, chemotherapy, external radiotherapy, internal radiotherapy/brachytherapy[9]Standard option (per NHS)main treatment, adjuvant/post-surgery treatment, advanced/recurrent/spread disease, symptom-control contexts. · NHS guidance is broad; dose, chemotherapy agent, brachytherapy plan, and intent depend on specialist staging and multidisciplinary review. Confidence/conflicts: medium-high for broad UK treatment categories; no conflict identified.
  • pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab[8]NICE recommendedPD-L1 combined positive score at least 1; persistent, recurrent, or metastatic cervical cancer in adults with PD-L1 CPS >=1. · NICE recommendation is for England/NICE context and includes stopping and commercial-arrangement conditions. Devolved-nation access and local implementation should be checked. Confidence/conflicts: high for NICE recommendation; no conflict identified.
  • tisotumab vedotin (Tivdak)[10]Approvedrecurrent or metastatic cervical cancer after progression on or after systemic treatment. · NICE TA1164 was published 2026-06-11. Operational funding timing, devolved-nation access, and local formulary implementation should be checked. Confidence/conflicts: high for NICE recommendation; no conflict identified.

Japan

  • bevacizumab (Avastin)[11]PMDA-approved (Japan)advanced or recurrent cervical cancer. · PMDA list confirms the indication but not regimen partners or contraindications. Current Japanese label and bleeding/fistula/thromboembolism risk precautions should be reviewed. Confidence/conflicts: high for PMDA approval-list entry; no conflict identified. Availability/reimbursement outside the approving regulator not established.
  • cemiplimab (Libtayo)[11]PMDA-approved (Japan)advanced or recurrent cervical cancer that has progressed after cancer chemotherapy. · The list does not provide full label restrictions or sequencing with other immunotherapy options. Current Japanese package insert and reimbursement should be checked. Confidence/conflicts: high for approval existence and setting; label/reimbursement details require refresh. No conflict identified.
  • cisplatin (Randa) and paclitaxel[11]PMDA-approved (Japan)cervical cancer for cisplatin dosage; advanced or recurrent cervical cancer for paclitaxel dosage. · The PMDA list identifies approvals/new dosage entries, not a complete regimen guideline. Confirm regimen partners, sequencing, and radiotherapy integration in Japanese guidelines/labels. Confidence/conflicts: high for PMDA approval-list entries; regimen-level context remains a gap. No conflict identified. Availability/reimbursement outside the approving regulator not established.
  • pembrolizumab (Keytruda)[11]PMDA-approved (Japan)locally advanced cervical cancer. · The approved-drug list does not state the full regimen or biomarker/chemoradiotherapy details; current Japanese electronic package insert should be checked before patient-facing reuse. Confidence/conflicts: high for Japan approval existence; regimen-level details need label refresh. No conflict identified. Availability/reimbursement outside the approving regulator not established.
  • tisotumab vedotin (Tivdak)[11]PMDA-approved (Japan)advanced or recurrent cervical cancer that has progressed after cancer chemotherapy. · The PMDA list is not a full label; ocular precautions, monitoring, and reimbursement status require current Japanese package-insert review. Confidence/conflicts: high for PMDA approval-list entry; label/reimbursement details require refresh. No conflict identified.

Russia

Thailand

  • Bevacizumab biosimilar (Zirabev) with paclitaxel and cisplatin or paclitaxel and topotecan[13]ApprovedNot biomarker-selected; Persistent, recurrent, or metastatic cervical carcinoma. · NDI supports indication text but not reimbursement, brand interchangeability, or suitability in patients with bleeding, fistula, wound-healing, hypertension, proteinuria, or thrombotic risks. Confidence/conflicts: High for Thai NDI indication text; reimbursement and individual suitability not established.
  • Bevacizumab biosimilar (Zirabev) with paclitaxel and cisplatin or paclitaxel and topotecan[13]ApprovedNot biomarker-selected; Persistent, recurrent, or metastatic cervical carcinoma. · NDI supports indication text but not reimbursement, brand interchangeability, or suitability in patients with bleeding, fistula, wound-healing, hypertension, proteinuria, or thrombotic risks. Confidence/conflicts: High for Thai NDI indication text; reimbursement and individual suitability not established.
  • Pembrolizumab (Keytruda) with chemoradiotherapy (CRT)[14]ApprovedNot biomarker-selected in the Thai indication text; High-risk locally advanced cervical cancer treated with chemoradiotherapy. · NDI prescribing document supports indication text but does not establish reimbursement, national-benefit coverage, radiation-center access, or individual eligibility. Thai-language clinical fields need human review. Confidence/conflicts: High for Thai NDI indication text; payer/access not established. Primary source is in Thai. English summary pending human review — confirm exact wording with your care team.
  • Pembrolizumab (Keytruda) with chemoradiotherapy (CRT)[14]ApprovedNot biomarker-selected in the Thai indication text; High-risk locally advanced cervical cancer treated with chemoradiotherapy. · NDI prescribing document supports indication text but does not establish reimbursement, national-benefit coverage, radiation-center access, or individual eligibility. Thai-language clinical fields need human review. Confidence/conflicts: High for Thai NDI indication text; payer/access not established. Primary source is in Thai. English summary pending human review — confirm exact wording with your care team.
  • Pembrolizumab (Keytruda) with chemoradiotherapy (CRT)[14]ApprovedNot biomarker-selected in the Thai indication text; High-risk locally advanced cervical cancer treated with chemoradiotherapy. · NDI prescribing document supports indication text but does not establish reimbursement, national-benefit coverage, radiation-center access, or individual eligibility. Thai-language clinical fields need human review. Confidence/conflicts: High for Thai NDI indication text; payer/access not established. Primary source is in Thai. English summary pending human review — confirm exact wording with your care team.
  • Pembrolizumab (Keytruda) with chemotherapy with or without bevacizumab; pembrolizumab monotherapy for PD-L1 CPS >=1 recurrent/metastatic disease after chemotherapy[15]ApprovedPD-L1 CPS status is not stated for the combination indication in fetched Thai excerpt; PD-L1 CPS >=1 is stated for monotherapy; Persistent/recurrent/metastatic disease for combination therapy; recurrent/metastatic post-chemotherapy PD-L1 CPS >=1 for monotherapy. · NDI supports indication text but not reimbursement, PD-L1 testing access, bevacizumab access, or sequence selection. Confidence/conflicts: High for Thai NDI indication text; reimbursement and testing/access details not established. Primary source is in Thai. English summary pending human review — confirm exact wording with your care team.
  • Pembrolizumab (Keytruda) with chemotherapy with or without bevacizumab; pembrolizumab monotherapy for PD-L1 CPS >=1 recurrent/metastatic disease after chemotherapy[15]ApprovedPD-L1 CPS status is not stated for the combination indication in fetched Thai excerpt; PD-L1 CPS >=1 is stated for monotherapy; Persistent/recurrent/metastatic disease for combination therapy; recurrent/metastatic post-chemotherapy PD-L1 CPS >=1 for monotherapy. · NDI supports indication text but not reimbursement, PD-L1 testing access, bevacizumab access, or sequence selection. Confidence/conflicts: High for Thai NDI indication text; reimbursement and testing/access details not established. Primary source is in Thai. English summary pending human review — confirm exact wording with your care team.

출처

  1. U.S. Food and Drug Administration — official drug label · official drug label
  2. National Cancer Institute (NCI) — national cancer agency evidence summary · national cancer agency evidence summary
  3. U.S. Food and Drug Administration (FDA) — regulator approval notice · regulator approval notice
  4. U.S. Food and Drug Administration (FDA) — regulator approval notice · regulator approval notice
  5. European Medicines Agency — regulator product page / EPAR · regulator product page / EPAR
  6. European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
  7. European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
  8. National Institute for Health and Care Excellence (NICE) — health technology appraisal / guideline · health technology appraisal / guideline
  9. NHS — national health service patient treatment guidance · national health service patient treatment guidance
  10. National Institute for Health and Care Excellence (NICE) — technology appraisal guidance · technology appraisal guidance
  11. Pharmaceuticals and Medical Devices Agency (PMDA) — regulator approved-drug list · regulator approved-drug list
  12. Russian Society of Clinical Oncology (RUSSCO) / RosOncoWeb — professional society clinical recommendations PDF · professional society clinical recommendations PDF
  13. Thai National Drug Information / Thai FDA-MOPH — prescribing information PDF / regulator drug-information repository · prescribing information PDF / regulator drug-information repository
  14. Thai National Drug Information / Thai FDA-MOPH — prescribing information PDF / regulator drug-information repository · prescribing information PDF / regulator drug-information repository
  15. Thai National Drug Information / Thai FDA-MOPH — prescribing information PDF / regulator drug-information repository · prescribing information PDF / regulator drug-information repository

위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026-06-12.